The combined expertise creates a key player in the North American analytical market
Neopharm Labs, a leading Quebec-based full-service pharmaceutical testing laboratory, announces its expansion into the United States with the strategic acquisition of Averica Discovery Services, a contract research organisation (CRO) based in the Greater Boston area with specialised expertise in early stage contract research and analytical development.
The addition of Averica to Neopharm Labs’ portfolio provides an opportunity for the organisation to expand its geographic reach into the US, allowing it to pursue its growth strategy and further increase its range of services into the region.
'We are very impressed with the knowledge and scientific track record of Dr Jeffrey Kiplinger and the entire Averica team. The combination of the companies makes us more competitive and allows us to broaden our service offerings to the life sciences industry. Our clients will directly benefit from the merging of our companies’ skills and talents,' states Nicolas Fortin, President and General Manager of Neopharm Labs.
The highly complementary combination of these two companies is unique. The new entity provides a range of services at every stage of the drug development cycle, from R&D to method development and validation, to stability management, and to commercial testing in chemistry and microbiology.
By acquiring Averica’s specialized expertise in small molecule analysis and purification, Neopharm is creating a company that will be a leader in the field of analytical services.
'Our clients can now take advantage of an expanded range of services,' adds Dr Jeffrey Kiplinger, President and CEO of Averica Discovery, who joins Neopharm’s Executive Team as Vice President, Science and Innovation.
'With this expansion into the US market, Neopharm Labs will continue building on our combined strengths and capabilities to provide the very best services to its customers alike.'
Averica’s Boston area laboratory will continue to provide its current services with plans to expand service offerings and lab space. The location will also serve as the U.S. sales office for Neopharm Labs.